Fig. 1 · Structure

Documents & Downloads

Licofelone

Cat. No. A11697 CAS 156897-06-2

COX/LOX inhibitor

Licofelone is a dual COX/LOX inhibitor, being considered as a treatment for osteoarthritis. It may reduce the gastrointestinal toxicity associated with other non-steroidal anti-inflammatory drugs, which only inhibit COX (cyclooxygenase). Licofelone is the first drug to inhibit both.

In Stock

Publications for Licofelone

1 publication citing this product

  1. Silke Neumann, .et al. , Front Immunol, 2016, 7: 537 PMID: 27994586

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Licofelone inhibits cellular 5-lipoxygenase (5-LO) product formation with strong assay dependence. In human PMNL, the reported IC50 was 2.3 µM after ionophore stimulation, versus ≥30 µM under cell-stress conditions. At 10 µM, licofelone did not significantly inhibit the tested cell-free 5-LO preparations. Cellular pathway inhibition therefore should not be equated with potent direct inhibition of isolated 5-LO. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
COX IC50 0.21 μM
5-LOX IC50 0.18 μM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 6 μM Inhibition of mPGES1 in IL1-beta treated human A549 cell microsomal membrane assessed as blockade of PGH2 to PGE2 conversion after 1 min [PMID: 19719242]
A549 IC50 6.7 μM Inhibition of mPGES1 in IL1-beta treated human A549 cell microsomal membrane assessed as residual enzyme activity after 1 min by measuring PGE2 level using RP-HPLC method [PMID: 19719242]
HeLa IC50 6 μM Inhibition of mPGES1 in human HeLa cells assessed as reduction in TNF-alpha induced PGE2 production preincubated for 2 hrs followed by TNF-alpha addition for 24 hrs by ELISA [PMID: 27597418]
HT-29 IC50 21.1 μM Cytotoxicity against COX-2 positive human HT-29 cells transfected with CD44v6shRNA assessed as growth inhibition after 48 hrs by MTT assay [PMID: 24295787]
HT-29 IC50 67 μM Cytotoxicity against COX-2 positive human HT-29 cells assessed as growth inhibition by CellTiter-96 AQueous assay [PMID: 24295787]
MCF7 IC50 36.7 μM Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs [PMID: 21295381]
MDA-MB-231 IC50 5.5 μM Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs [PMID: 21295381]
SW480 IC50 68 μM Cytotoxicity against COX-2 negative human SW480 cells assessed as growth inhibition by CellTiter-96 AQueous assay [PMID: 24295787]

Licofelone Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Licofelone from 3 published references. In vitro models include freshly isolated human polymorphonuclear leukocytes (PMNL).

Licofelone In Vitro Studies

In GM-CSF/PGE2-conditioned naïve mouse bone-marrow cultures, licofelone reduced IMC frequencies at 2.5 and 5 µM and macrophage frequencies at 2.5–10 µM after 5 days. The IMC response at 10 µM was not significant, and CD11c+ cell frequencies were unchanged. These are live-cell population frequencies, not absolute cell counts. [2]

Cellular versus cell-free 5-LO product inhibition

Biochemical assay · Human PMNL, PMNL homogenates, and partially purified recombinant human 5-LO [1]

Licofelone at 10 µM inhibited 5-LO product formation in intact PMNL but did not significantly inhibit the cell-free preparations; the direct inhibitor BWA4C remained active. Adding DTT did not significantly restore inhibition in PMNL homogenates.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
5-LO product formation: intact cells versus homogenates and partially purified enzymeQualitative activity comparison 10 µM licofelone: no significant suppression in cell-free assays; inhibition in intact PMNL[1]
Effect of reducing conditions on licofelone inhibition in PMNL homogenatesQualitative rescue control DTT did not significantly restore inhibition (P > 0.05)[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM in Figure 3a; concentration series up to 10 µM in Figure 3b
Exposure duration
Intact PMNL: 15-min pretreatment; cell-free Figure 3a: 5-min pretreatment; product formation measured after 10 min in shared methods
Method
In vitro addition; arachidonic acid 40 µM for Figure 3a; intact cells activated by A23187, cell-free preparations by calcium
Vehicle
DMSO
Co-treatment
No therapeutic combination; MK-886 and BWA4C are parallel comparator treatments
Reported limits
Figure 3a caption specifies 1 mM Ca2+ whereas general cell-free methods specify 2 mM CaCl2. Exact calcium concentration is unresolved; no calcium-dependent comparison or cell-free IC50 is claimed.
Methods and source locations

Compound reported in the paper: Licofelone; Compound label in the paper: ML3000

Evidence applies to the reported licofelone material and experimental context; no validation of the current A11697 lot or equivalence of formulations.

Figure 3a–b; shared “Determination of 5-LO product formation” methods; Statistics; Reagents

5-LO product formation: intact cells versus homogenates and partially purified enzyme: HPLC of summed 5-LO products; DMSO vehicle; MK-886 1 µM and BWA4C 1 µM comparators. Mean + s.e., n = 4; ANOVA/Tukey-HSD. — Figure 3a and Results, “Licofelone is a weak inhibitor of 5-LO activity in cell-free assays”

Effect of reducing conditions on licofelone inhibition in PMNL homogenates: Figure 3b: with/without 1 mM DTT across 2, 10 or 40 µM arachidonic acid; mean + s.e., n = 4; ANOVA/Tukey-HSD. — Figure 3b and corresponding Results

Stimulus-dependent inhibition of the cellular 5-LO pathway

Cell-based study · Freshly isolated human polymorphonuclear leukocytes (PMNL) [1]

Licofelone suppressed ionophore-induced 5-LO product formation more potently than product formation induced by hyperosmotic or genotoxic stress. Diamide also reduced efficacy in ionophore-stimulated cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
5-LO product formation after ionophore plus arachidonic acidIC50 2.3 µM[1]
5-LO product formation after hyperosmotic or genotoxic stressIC50 ≥30 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Licofelone concentration series through 30 µM
Exposure duration
15-min total pretreatment; stress agents added for final 3 min; 10-min product formation period
Method
Intact-cell assay at 37°C; arachidonic acid 40 µM. Ionophore stimulation compared with NaCl 300 mM or sodium arsenite 10 µM; diamide 500 µM is an additional oxidant condition
Vehicle
DMSO
Co-treatment
No therapeutic combination; MK-886 tested in parallel
Reported limits
Donor number is not specified for this figure; reported n = 4–5 is retained without reinterpreting it.
Methods and source locations

Compound reported in the paper: Licofelone; Compound label in the paper: ML3000

Evidence applies to the reported licofelone material and experimental context; no validation of the current A11697 lot or equivalence of formulations.

Figure 4; corresponding Results; intact-cell HPLC methods; Statistics; Reagents

5-LO product formation after ionophore plus arachidonic acid: HPLC; A23187 2.5 µM plus arachidonic acid 40 µM; DMSO vehicle and MK-886 comparator. Figure values mean + s.e., n = 4–5. — Figure 4 and Results, “The potency of licofelone depends on the stimulus to activate 5-LO”

5-LO product formation after hyperosmotic or genotoxic stress: HPLC; NaCl or sodium arsenite with arachidonic acid. Results report this bound for cell-stress conditions; it is not an exact curve estimate. — Figure 4 and corresponding Results

Licofelone alters myeloid-cell frequencies in bone-marrow cultures

Cell-based study · Bone-marrow cells from naïve C57BL/6 mice, cultured under GM-CSF/PGE2 differentiation conditions [2]

Licofelone reduced the live-cell frequency of Gr-1+ CD11b+ IMCs at 2.5 and 5 µM, but the 10 µM IMC response was not significant. F4/80+ CD11b+ Gr-1− macrophage frequencies were reduced at all three concentrations. CD11c+ cell frequencies were unchanged.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Frequency of IMCs, macrophages and CD11c+ cells among live cellsFlow-cytometric population frequencies IMCs: reduction at 2.5 and 5 µM; no significant reduction at 10 µM. Macrophages: reduction at 2.5, 5 and 10 µM. CD11c+ cells: no significant effect.[2]

Literature-Reported Treatment Conditions

Treatment concentration
2.5, 5 and 10 µM
Exposure duration
5 days; licofelone, medium and cytokines refreshed every other day
Method
Addition to naïve bone-marrow cultures containing GM-CSF 20 ng/mL and PGE2 9.1 µg/mL
Co-treatment
GM-CSF and PGE2 are differentiation stimuli, not an antitumor combination treatment
Reported limits
Licofelone solvent/vehicle is not specified in the retrieved materials or IMC-generation methods. Figure 5 uses the 0 µM licofelone culture control. Absolute cell counts and a monotonic dose response are not established.
Methods and source locations

Compound reported in the paper: Licofelone

Evidence applies to the reported licofelone material and experimental context; no validation of the current A11697 lot or equivalence of formulations.

Figure 5A–C; Materials; “Generation and Phenotyping of IMCs”; Statistical Analysis; corresponding Results

Frequency of IMCs, macrophages and CD11c+ cells among live cells: Propidium-iodide-low live-cell gate; mean + SD, three independent experiments, n = 2/experiment; one-way ANOVA with Tukey comparison. Exact percentages are not inferred from bars. — Figure 5A–C and Results, “Licofelone Suppresses the Generation of Gr-1+ CD11b+ IMCs and Gr-1− F4/80+ Macrophages In Vitro”

Licofelone In Vivo Studies

In a canine surgical osteoarthritis model, oral licofelone at total daily doses of 2.5 or 5.0 mg/kg for 8 weeks reduced cartilage MMP-13 mRNA and immunostaining versus placebo. ADAMTS-5 responses in the same study were limited: decreases did not reach statistical significance. These findings concern cartilage markers in this model. [3]

Cartilage catabolic markers after oral licofelone in canine osteoarthritis

Animal study · Adult crossbred dogs with right-knee anterior cruciate ligament sectioning; OA placebo and normal untreated controls [3]

Oral licofelone reduced cartilage MMP-13 mRNA and immunostaining at both daily doses. In the same design, ADAMTS-5 showed little treatment response and the decreases did not reach statistical significance. These tissue endpoints do not establish direct inhibition of these enzymes.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cartilage MMP-13 transcript abundance and percentage of immunopositive chondrocytesRelative mRNA and immunohistomorphometry Significantly reduced at both 2.5 and 5.0 mg/kg/day versus OA placebo[3]
Cartilage ADAMTS-5 transcript abundance and immunostainingLimiting response Little treatment effect; decreases did not reach statistical significance[3]

Conditions shared by the study groups

Route
Oral
Frequency
Twice daily at 8 a.m. and 4 p.m., with food
Treatment course
8 weeks, beginning the day after ACL sectioning
Vehicle
Encapsulated material; drug capsule excipient not specified
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
2.5 mg/kg/day licofelone
2.5 mg/kg/day total
OA dogs receiving encapsulated methylcellulose placebo; normal unoperated untreated dogs also includedMMP-13 mRNA and immunostaining reduced versus OA placebo; ADAMTS-5 treatment differences did not reach significance.[3]
5.0 mg/kg/day licofelone
5.0 mg/kg/day total
OA dogs receiving encapsulated methylcellulose placebo; normal unoperated untreated dogs also includedMMP-13 mRNA and immunostaining reduced versus OA placebo; ADAMTS-5 treatment differences did not reach significance.[3]
2.5 mg/kg/day licofelone
Model: Adult crossbred dogs, 2–3 years old, 20–25 kg
Reported limits: Nominal cohort n = 7 per operated group; immunohistochemistry n = 5/group; PCR analytic n not explicitly stated in the selected methods/caption.
5.0 mg/kg/day licofelone
Model: Adult crossbred dogs, 2–3 years old, 20–25 kg
Reported limits: Nominal cohort n = 7 per operated group; immunohistochemistry n = 5/group; PCR analytic n not explicitly stated in the selected methods/caption.
Methods and source locations

Compound reported in the paper: Licofelone

Evidence applies to the reported licofelone material and experimental context; no validation of the current A11697 lot or equivalence of formulations.

Experimental groups; specimen selection; shared immunohistochemistry/controls, morphometry and PCR/statistics; Figures 1 and 3; corresponding Results and ADAMTS-5 Discussion

Cartilage MMP-13 transcript abundance and percentage of immunopositive chondrocytes: Real-time quantitative PCR normalized to GAPDH and blinded immunostaining scores; median/range box plots; Mann–Whitney U comparison. Immunohistochemistry n = 5/group; cohort n = 7 per operated group. — Figure 1a–c; MMP-13 gene expression and protein synthesis; shared PCR and immunohistochemistry methods

Cartilage ADAMTS-5 transcript abundance and immunostaining: Real-time quantitative PCR and immunohistochemistry; median/range displays. Elevated OA protein staining relative to normal does not imply significant licofelone suppression. — Figure 3a–c; Results, ADAMTS-4 and ADAMTS-5 gene expression and protein synthesis; Discussion, ADAMTS-5 paragraph

2.5 mg/kg/day licofelone · Materials and methods, Experimental groups; Figures 1 and 3; corresponding Results

5.0 mg/kg/day licofelone · Materials and methods, Experimental groups; Figures 1 and 3; corresponding Results

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 156897-06-2
Applications COX/LOX inhibitor
Formula C23H22ClNO2
Molecular Weight 379.88
SMILES
CC1(CC2=C(C(=C(N2C1)CC(=O)O)C3=CC=C(C=C3)Cl)C4=CC=CC=C4)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 16 mg/mL (42.11 mM)
Water Insoluble
Ethanol 3 mg/mL (7.89 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Licofelone Research References

  1. [1] Fischer L, Hornig M, Pergola C, et al. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products British journal of pharmacology (2007). PMID: 17704828 DOI: 10.1038/sj.bjp.0707416 Source material
  2. [2] Neumann S, Shirley SA, Kemp RA, et al. Improved Antitumor Activity of a Therapeutic Melanoma Vaccine through the Use of the Dual COX-2/5-LO Inhibitor Licofelone Frontiers in immunology (2016). PMID: 27994586 DOI: 10.3389/fimmu.2016.00537 Source material
  3. [3] Pelletier JP, Boileau C, Boily M, et al. The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases Arthritis research & therapy (2005). PMID: 16207326 DOI: 10.1186/ar1788 Source material

Publications

1 publication citing this product

  1. Silke Neumann, .et al. , Front Immunol, 2016, 7: 537 PMID: 27994586

Added to your cart

View Cart Checkout
Loading...